• Je něco špatně v tomto záznamu ?

Multimorbidity and frailty are associated with poorer SARS-CoV-2-related outcomes: systematic review of population-based studies

TT. Makovski, J. Ghattas, S. Monnier-Besnard, L. Cavillot, M. Ambrožová, B. Vašinová, R. Feteira-Santos, P. Bezzegh, FP. Bollmann, J. Cottam, R. Haneef, B. Devleesschauwer, N. Speybroeck, PJ. Nogueira, MJ. Forjaz, J. Coste, L. Carcaillon-Bentata

. 2024 ; 36 (1) : 40. [pub] 20240214

Jazyk angličtina Země Německo

Typ dokumentu systematický přehled

Perzistentní odkaz   https://www.medvik.cz/link/bmc24007141

BACKGROUND: Estimating the risks and impacts of COVID-19 for different health groups at the population level is essential for orienting public health measures. Adopting a population-based approach, we conducted a systematic review to explore: (1) the etiological role of multimorbidity and frailty in developing SARS-CoV-2 infection and COVID-19-related short-term outcomes; and (2) the prognostic role of multimorbidity and frailty in developing short- and long-term outcomes. This review presents the state of the evidence in the early years of the pandemic. It was conducted within the European Union Horizon 2020 program (No: 101018317); Prospero registration: CRD42021249444. METHODS: PubMed, Embase, World Health Organisation COVID-19 Global literature on coronavirus disease, and PsycINFO were searched between January 2020 and 7 April 2021 for multimorbidity and 1 February 2022 for frailty. Quantitative peer-reviewed studies published in English with population-representative samples and validated multimorbidity and frailty tools were considered. RESULTS: Overall, 9,701 records were screened by title/abstract and 267 with full text. Finally, 14 studies were retained for multimorbidity (etiological role, n = 2; prognostic, n = 13) and 5 for frailty (etiological role, n = 2; prognostic, n = 4). Only short-term outcomes, mainly mortality, were identified. An elevated likelihood of poorer outcomes was associated with an increasing number of diseases, a higher Charlson Comorbidity Index, different disease combinations, and an increasing frailty level. DISCUSSION: Future studies, which include the effects of recent virus variants, repeated exposure and vaccination, will be useful for comparing the possible evolution of the associations observed in the earlier waves.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007141
003      
CZ-PrNML
005      
20240423155739.0
007      
ta
008      
240412s2024 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s40520-023-02685-4 $2 doi
035    __
$a (PubMed)38353841
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Makovski, Tatjana T $u Department of Non-Communicable Diseases and Injuries, French Public Health Agency (Santé publique France), Saint-Maurice, France. tatjana.makovski@santepubliquefrance.fr
245    10
$a Multimorbidity and frailty are associated with poorer SARS-CoV-2-related outcomes: systematic review of population-based studies / $c TT. Makovski, J. Ghattas, S. Monnier-Besnard, L. Cavillot, M. Ambrožová, B. Vašinová, R. Feteira-Santos, P. Bezzegh, FP. Bollmann, J. Cottam, R. Haneef, B. Devleesschauwer, N. Speybroeck, PJ. Nogueira, MJ. Forjaz, J. Coste, L. Carcaillon-Bentata
520    9_
$a BACKGROUND: Estimating the risks and impacts of COVID-19 for different health groups at the population level is essential for orienting public health measures. Adopting a population-based approach, we conducted a systematic review to explore: (1) the etiological role of multimorbidity and frailty in developing SARS-CoV-2 infection and COVID-19-related short-term outcomes; and (2) the prognostic role of multimorbidity and frailty in developing short- and long-term outcomes. This review presents the state of the evidence in the early years of the pandemic. It was conducted within the European Union Horizon 2020 program (No: 101018317); Prospero registration: CRD42021249444. METHODS: PubMed, Embase, World Health Organisation COVID-19 Global literature on coronavirus disease, and PsycINFO were searched between January 2020 and 7 April 2021 for multimorbidity and 1 February 2022 for frailty. Quantitative peer-reviewed studies published in English with population-representative samples and validated multimorbidity and frailty tools were considered. RESULTS: Overall, 9,701 records were screened by title/abstract and 267 with full text. Finally, 14 studies were retained for multimorbidity (etiological role, n = 2; prognostic, n = 13) and 5 for frailty (etiological role, n = 2; prognostic, n = 4). Only short-term outcomes, mainly mortality, were identified. An elevated likelihood of poorer outcomes was associated with an increasing number of diseases, a higher Charlson Comorbidity Index, different disease combinations, and an increasing frailty level. DISCUSSION: Future studies, which include the effects of recent virus variants, repeated exposure and vaccination, will be useful for comparing the possible evolution of the associations observed in the earlier waves.
650    _2
$a lidé $7 D006801
650    _2
$a SARS-CoV-2 $7 D000086402
650    12
$a COVID-19 $x epidemiologie $7 D000086382
650    12
$a křehkost $x epidemiologie $7 D000073496
650    _2
$a multimorbidita $7 D000076322
650    _2
$a Evropská unie $7 D005062
655    _2
$a systematický přehled $7 D000078182
700    1_
$a Ghattas, Jinane $u Institute of Health and Society (IRSS), Université catholique de Louvain, Brussels, Belgium $u Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium
700    1_
$a Monnier-Besnard, Stéphanie $u Department of Non-Communicable Diseases and Injuries, French Public Health Agency (Santé publique France), Saint-Maurice, France
700    1_
$a Cavillot, Lisa $u Institute of Health and Society (IRSS), Université catholique de Louvain, Brussels, Belgium $u Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium
700    1_
$a Ambrožová, Monika $u National screening centre, Institute of Health Information and Statistics of the Czech Republic, Prague, Czech Republic $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Vašinová, Barbora $u National screening centre, Institute of Health Information and Statistics of the Czech Republic, Prague, Czech Republic
700    1_
$a Feteira-Santos, Rodrigo $u Área Disciplinar Autónoma de Bioestatística, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal $u Laboratório Associado TERRA, Instituto de Saúde Ambiental, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
700    1_
$a Bezzegh, Peter $u Directorate for Project Management, National Directorate General for Hospitals, Budapest, Hungary
700    1_
$a Bollmann, Felipe Ponce $u Universidad Nacional de Educación a Distancia, Madrid, Spain
700    1_
$a Cottam, James $u Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium $u Institute of Tropical Medicine, Antwerp, Belgium
700    1_
$a Haneef, Romana $u Department of Non-Communicable Diseases and Injuries, French Public Health Agency (Santé publique France), Saint-Maurice, France
700    1_
$a Devleesschauwer, Brecht $u Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium $u Department of Translational Physiology, Infectiology and Public Health, Ghent University, Merelbeke, Belgium
700    1_
$a Speybroeck, Niko $u Institute of Health and Society (IRSS), Université catholique de Louvain, Brussels, Belgium
700    1_
$a Nogueira, Paulo Jorge $u Área Disciplinar Autónoma de Bioestatística, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal $u Laboratório Associado TERRA, Instituto de Saúde Ambiental, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal $u Centro de Investigação Em Saúde Pública, Escola Nacional de Saúde Pública, ENSP, CISP, Comprehensive Health Research Center, CHRC, Universidade NOVA de Lisboa, Lisbon, Portugal $u CIDNUR-Centro de Investigação, Inovação e Desenvolvimento Em Enfermagem de Lisboa Escola Superior de Enfermagem de Lisboa, Avenida Professor Egas Moniz, 1600-190, Lisbon, Portugal
700    1_
$a Forjaz, Maria João $u National Center of Epidemiology, Instituto de Salud Carlos III, RICAPPS, Madrid, Spain
700    1_
$a Coste, Joël $u Department of Non-Communicable Diseases and Injuries, French Public Health Agency (Santé publique France), Saint-Maurice, France
700    1_
$a Carcaillon-Bentata, Laure $u Department of Non-Communicable Diseases and Injuries, French Public Health Agency (Santé publique France), Saint-Maurice, France
773    0_
$w MED00159812 $t Aging clinical and experimental research $x 1720-8319 $g Roč. 36, č. 1 (2024), s. 40
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38353841 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155736 $b ABA008
999    __
$a ok $b bmc $g 2081247 $s 1216908
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 36 $c 1 $d 40 $e 20240214 $i 1720-8319 $m Aging clinical and experimental research $n Aging Clin Exp Res $x MED00159812
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace